Gilead Sciences Inc (NASDAQ:GILD) stock is up 5.7%, hitting a record high of $155.56 at last glance, after the biopharmaceutical company announced a top- and bottom-line win for the fourth quarter. Shares are also brushing off a lackluster product revenue outlook for 2026, which is expected to range from $29.6 to $30 billion, below analysts' estimates.
The security has already attracted 11 price-target hikes, including one from Scotiabank to $177 from $140. Analysts already lean bullish toward GILD, with 24 of 30 firms in coverage sporting a "buy" or better rating. The 12-month consensus target price of $150.36 is still a 1.7% discount to current levels, though, justifying today's big wave of price-target hikes.
Shares pared premarket losses and are now on track for their best single-day percentage gain since August. The equity now sports a 59.8% year-over-year lead, with 25.3% added so far in 2026.
Though calls still outpace puts on an overall basis, options traders have been much more bearish than usual. This is per the security's 50-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) that sits higher than 76% of annual readings. An unwinding of this pessimism could create additional tailwinds for GILD.
